DMF Initiation Dose and Baseline Investigations
Start dimethyl fumarate at 120 mg twice daily for 7 days, then increase to the maintenance dose of 240 mg twice daily. 1
Initiation Dosing Protocol
The FDA-approved dosing regimen is straightforward 1:
- Week 1 (Days 1-7): 120 mg twice daily (starter dose)
- Week 2 onwards: 240 mg twice daily (maintenance dose)
Key dosing considerations:
- Patients receive two different capsule strengths when starting: 120 mg for the first week and 240 mg for maintenance 1
- Capsules must be swallowed whole and intact—never crushed, chewed, or sprinkled on food 1
- Can be taken with or without food, though taking with food may reduce flushing 1
- If the maintenance dose is not tolerated, temporary reduction to 120 mg twice daily is acceptable, but return to 240 mg twice daily should occur within 4 weeks 1
- Discontinue if unable to tolerate return to maintenance dose 1
The three-times-daily dosing (720 mg total) showed no additional benefit over twice-daily dosing in clinical trials and is not recommended 1.
Required Baseline Investigations
Before initiating DMF, obtain the following mandatory tests 1:
Hematologic Testing
- Complete blood count (CBC) with differential, including absolute lymphocyte count (ALC) 1
- Critical because DMF causes lymphopenia in most patients
- Establishes baseline for monitoring progressive multifocal leukoencephalopathy (PML) risk
Hepatic Function
- Serum aminotransferases (ALT/AST)
- Alkaline phosphatase
- Total bilirubin 1
- DMF can cause liver injury; baseline values essential for comparison
Additional Considerations
- Pregnancy test if indicated (DMF safety in pregnancy not established) 1
Strategies to Improve Tolerability
To minimize common adverse events (flushing and GI symptoms):
- Administer with food, particularly high-fat foods like peanut butter or sausage 2
- Consider aspirin prophylaxis: 325 mg taken 30 minutes before DMF during the first month reduces flushing without worsening GI events 1, 2
- Counsel patients extensively that flushing and GI symptoms (nausea, diarrhea, abdominal pain) are common in the first few months but typically transient 2
Critical Safety Warnings
Absolute contraindication: Known hypersensitivity to DMF or excipients (risk of anaphylaxis and angioedema) 1
Monitor for serious complications:
- PML risk: Instruct patients to report progressive weakness, vision changes, cognitive changes, or personality changes immediately 1
- Lymphopenia: Recheck CBC at 6 months, then every 6-12 months thereafter 1
- Liver injury: Educate patients to report fatigue, anorexia, right upper quadrant pain, dark urine, or jaundice 1
- Herpes zoster and opportunistic infections: Higher risk with prolonged lymphopenia 1
Common Pitfalls to Avoid
- Don't skip the 7-day starter dose—jumping directly to 240 mg twice daily significantly increases GI intolerance
- Don't allow patients to crush capsules—the delayed-release formulation is designed to minimize GI side effects
- Don't forget baseline labs—you cannot monitor for lymphopenia or hepatotoxicity without baseline values
- Don't dismiss early GI symptoms—proactive management with food timing and temporary dose reduction prevents discontinuation
The evidence from psoriasis guidelines 3 describes fumaric acid esters (Fumaderm) with different formulations and dosing schedules that are not applicable to the FDA-approved DMF formulation for multiple sclerosis. The MS-specific FDA labeling 1 provides the definitive dosing and monitoring recommendations.